Kymera Therapeutics (NASDAQ:KYMR – Free Report) had its target price lifted by Guggenheim from $135.00 to $170.00 in a report released on Monday, Marketbeat Ratings reports. Guggenheim currently has a buy rating on the stock. Several other analysts have also recently commented on the company. B. Riley Financial raised their target price on Kymera Therapeutics […]

Maplight Therapeutics (NASDAQ:MPLT – Free Report) had its target price trimmed by Needham & Company LLC from $45.00 to $43.00 in a research report sent to investors on Monday, MarketBeat Ratings reports. The brokerage currently has a buy rating on the stock. Other equities analysts also recently issued research reports about the stock. Wolfe Research […]

Braze (NASDAQ:BRZE – Get Free Report) had its price target hoisted by equities research analysts at Oppenheimer from $30.00 to $36.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s target price points to a potential upside of 6.39% from the stock’s previous close. A number […]

Enliven Therapeutics (NASDAQ:ELVN – Free Report) had its target price upped by Mizuho from $62.00 to $73.00 in a research report report published on Tuesday,Benzinga reports. They currently have an outperform rating on the stock. A number of other brokerages have also issued reports on ELVN. Weiss Ratings reiterated a “sell (d-)” rating on shares […]

Intensity Therapeutics (NASDAQ:INTS – Free Report) had its price objective lifted by HC Wainwright from $5.00 to $7.00 in a report published on Tuesday, Marketbeat Ratings reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Intensity Therapeutics’ Q3 2026 earnings at ($1.11) EPS, Q4 2026 earnings at […]